Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection

• Status: Not yet recruiting
• Trial end date: 2023-09-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ciprian Gheorghe

Criteria

Inclusion Criteria:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Male or female, aged 18-85

• Diagnosed with q-PCR confirmed infection with SARS-Cov-2 virus and admitted to the hospital.

• Receiving non-invasive respiratory support through a nasal cannula or a face mask.

• Ability to take oral medication and be willing to adhere to the tazemetostat regimen.

Exclusion Criteria:

• Unable to take PO medication.

• Need for intubation or ECMO.

• Pregnancy or lactation

• Known allergic reactions to tazemetostat.

• Active malignancy (not in remission).

• Treatment with another investigational drug.